Neurosense Therapeutics Ltd- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Neurosense Therapeutics Ltd 公司

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Neurosense Therapeutics Ltd簡介



公司代碼NRSN

公司名稱Neurosense Therapeutics Ltd

上市日期Dec 09, 2021

CEOBen-Noon (Alon)

員工數量15

證券類型Ordinary Share

年結日Dec 09

公司地址11 Hamenofim St.

城市HERZLIYA

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Israel

郵編4672562

電話97297996183

網址https://www.neurosense-tx.com/

公司代碼NRSN

上市日期Dec 09, 2021

CEOBen-Noon (Alon)

Neurosense Therapeutics Ltd公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Alon Ben-Noon

Chief Executive Officer, Director

3.18M

+93666.00%

Mr. Or Eisenberg

Chief Financial Officer

480.92K

+20916.00%

Dr. Ferenc Tracik

Chief Medical Officer

189.62K

+66667.00%

Mr. Mark W. Leuchtenberger

Independent Non-Executive Chairman of the Board

64.00K

--

Mr. Cary J. Claiborne

Non-Executive Independent Director

24.00K

--

Ms. Christine A. Pellizzari, J.D.

Non-Executive Independent Director

--

Ms. Caren Deardorf

Non-Executive Independent Director

--

Dr. Revital Mandil-Levin, Ph.D.

Non-Executive Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Alon Ben-Noon

Chief Executive Officer, Director

3.18M

+93666.00%

Mr. Or Eisenberg

Chief Financial Officer

480.92K

+20916.00%

Dr. Ferenc Tracik

Chief Medical Officer

189.62K

+66667.00%

Mr. Mark W. Leuchtenberger

Independent Non-Executive Chairman of the Board

64.00K

--

Mr. Cary J. Claiborne

Non-Executive Independent Director

24.00K

--

Ms. Christine A. Pellizzari, J.D.

Non-Executive Independent Director

--

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 1月31日週六

持股股東

股東類型

持股股東

佔比

Ben-Noon (Alon)

10.69%

Rimon Gold Assets Ltd

7.76%

Eisenberg (Or)

1.62%

Tracik (Ferenc)

0.64%

Squarepoint Capital LLP

0.32%

其他

78.97%

持股股東

佔比

Ben-Noon (Alon)

10.69%

Rimon Gold Assets Ltd

7.76%

Eisenberg (Or)

1.62%

Tracik (Ferenc)

0.64%

Squarepoint Capital LLP

0.32%

其他

78.97%

股東類型

持股股東

佔比

Individual Investor

13.78%

Corporation

7.76%

Investment Advisor/Hedge Fund

0.37%

Investment Advisor

0.35%

Research Firm

0.15%

Hedge Fund

0.07%

Bank and Trust

0.05%

其他

77.47%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

30

293.14K

0.99%

-2.10M

2025Q3

29

437.13K

1.75%

-1.60M

2025Q2

37

7.64M

31.03%

+143.76K

2025Q1

39

7.45M

37.28%

+353.50K

2024Q4

38

7.90M

34.02%

+1.29M

2024Q3

32

5.18M

22.45%

-1.31M

2024Q2

35

6.62M

30.57%

+1.57M

2024Q1

38

5.18M

33.20%

-953.28K

2023Q4

38

5.12M

32.81%

-1.05M

2023Q3

33

5.76M

47.99%

-945.27K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Ben-Noon (Alon)

3.18M

10.69%

+93.67K

+3.04%

Apr 07, 2025

Rimon Gold Assets Ltd

2.30M

7.76%

+2.30M

--

Dec 02, 2024

Eisenberg (Or)

480.92K

1.62%

+20.92K

+4.55%

Apr 07, 2025

Tracik (Ferenc)

189.62K

0.64%

+66.67K

+54.22%

Apr 07, 2025

Squarepoint Capital LLP

95.38K

0.32%

+45.45K

+91.04%

Sep 30, 2025

Russek-Blum (Niva)

75.43K

0.25%

+10.00K

+15.28%

Apr 07, 2025

Leuchtenberger (Mark W)

64.00K

0.22%

--

Apr 07, 2025

Morgan Stanley & Co. LLC

41.40K

0.14%

-38.50K

-48.19%

Sep 30, 2025

Meitav Investment House Ltd

40.00K

0.13%

--

Sep 30, 2025

Binder (Hagit)

32.00K

0.11%

+10.00K

+45.45%

Apr 07, 2025

持股ETF



機構名稱

佔比

暫無數據

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據